Hansa Biopharma AB (publ) HNSBF
3.29 USD 0.00 (+0.00%)
At closeNov 3, 2026, 4:00 PM EST
2.93 Day range 2.93
2.90 52-week range 4.58
- YTD
- +13.02%
- 1 year
- -28.19%
- Market cap
- 328.02M
- EPS (ttm)
- -0.84
- YTD return
- +13.02%
- 1-year return
- -28.19%
- Volume
- 150
- Avg volume
- 93
- Open
- 2.93
- Previous close
- 3.29
- Day's range
- 2.93 – 2.93
- 52-week range
- 2.90 – 4.58
YTD +0.38 (+13.06%)
News
Hansa Biopharma announces positive Idefirix PAES results presented in the High-Impact Clinical Trials session at ASN Kidney Week 
Hansa Biopharma AB (publ) (OTCMKTS:HNSBF) Sees Large Increase in Short Interest 
Hansa Biopharma Partners with Cradle to Advance AI-Driven Protein Design and Engineering 
Hansa Biopharma announces first commercial kidney transplant patient treated with Idefirix in Australia 
Hansa Biopharma AB (publ) (HNSBF) Q2 2026 Earnings Call Transcript 
Hansa Biopharma participating in Wedbush PacGrow Renal Summit 
Hansa Biopharma announces closing of €115 million licensing transaction with SERB Pharmaceuticals for Idefirix in Europe and MENA 
Hansa Biopharma AB (publ) (HNSBF) Analyst/Investor Day Transcript 
Hansa Biopharma AB (publ) (HNSBF) Discusses Top Line Results from PAES Study on Imlifidase in Highly Sensitized Kidney Transplant Patients Transcript 
Hansa Biopharma reports positive efficacy and safety results from Idefirix® European post authorization study in kidney transplantation
Your note
Sign in to keep a note on HNSBF — it syncs with the Stock Master app.